Q4 2025 Xeris Biopharma Holdings Inc Earnings Call Transcript
Key Points
- Xeris Biopharma Holdings Inc (XERS) achieved financial self-sustainability in 2025, eliminating concerns about its ability to self-fund its strategy and pipeline.
- The company reported a 43% year-over-year revenue growth in Q4 2025, reaching nearly $86 million, and a 44% increase for the full year, totaling $292 million.
- Xeris Biopharma Holdings Inc (XERS) delivered nearly $60 million in adjusted EBITDA and reported net income on a full-year basis for the first time.
- Recorlev, a key growth driver, nearly doubled its patient base by the end of 2025, and the company expanded its commercial team to further increase awareness and adoption.
- The company is advancing its pipeline with XP-8121, a once-weekly subcutaneous levothyroxine injection, with plans to initiate a phase 3 trial in the second half of 2026, targeting a significant unmet medical need.
- Xeris Biopharma Holdings Inc (XERS) faces ongoing patent infringement litigation concerning Recorlev, which could pose legal and financial risks.
- The company anticipates a significant increase in R&D expenses by approximately $25 million in 2026 to support the phase 3 study for XP-8121.
- SG&A expenses are expected to rise by approximately $45 million in 2026 due to the expansion of the commercial team, impacting short-term profitability.
- The company does not provide specific product guidance, which may lead to uncertainty among investors regarding individual product performance.
- Xeris Biopharma Holdings Inc (XERS) faces potential competition from generic versions of Recorlev, which could impact its market share and revenue growth.
Hello everyone. Thank you for joining us and welcome to the Xeris BioPharma fourth quarter 2025 earnings conference call. (Operator Instructions). I will now hand the call over to Allison Wey, Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.
Thank you, Warren. Good morning and welcome to the Xeris BioPharma 2025 full year Financial results conference call. Earlier this morning we issued a press release detailing our 2025 financial and operating results and financial guidance for 2026. This press release is available on our website.
Joining me on the call today is John Shannon, our CEO, and Steve Pieper, our CFO. Following our prepared remarks, we'll open the call for questions. Before we begin, I'd like to remind you that today's discussion will include forward-looking statements regarding Xeris future expectations, plans, strategies, objectives, and financial performance.
These forward
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
